“…Studies in the CSR and corporate sustainability areas in the pharmaceutical industry have focused on various aspects, such as: the relation between engagement in CSR activities and positive financial results (Min, Desmoulins_Lebeaut & Esposito, 2017); challenges of reverse logistics management in the pharmaceutical industry (Luna & Vianna, 2019;Naryana & Elias, 2014); the management of the complex stakeholder network (O'Riodan & Fairbrass, 2008;O´Riodan & Fairbrass, 2014) as well as the issue of the industry's reputation (Fischer, 2009). Moreover, Singleton, Nissen, Barter and McIntosh (2014) in their literarture review cited the three main sources of the pharmaceutical huge negative impact in the enviroment: the carbon footprint of manufacturing and distribution chain; the incineration of unwanted pharmaceuticals, and the direct chemical effects of the pharmaceutical in nature (Kummerer, 2010), and suggested that pharmaceutics should have an action to reduce such impacts. However, no study was found in the literature which investigated barter in the pharmaceutical industry's sustainability.…”